title: 22q11.2 deletion syndrome: atypical antipsychotics and relapsing psychoses.
abstract: In their letter to the editor, Boot and colleagues comment on the results of treatment with atypical antipsychotics in patients with 22q11.2 deletion syndrome and relapsing psychoses. They identify 3 issues (i. e., description of study rationale and assessments, the importance of endocrine dysfunctions and possible effects of sample bias) and conclude that "until strong evidence to the contrary [is available], standard pharmacological management of psychotic illness in 22q11DS remains recommended." In our reply, we will illustrate the erroneous nature of their conjectures.
authors.affiliation: Vincent van Gogh Institut for Psychiatry, Centre of Excellence for Neuropsychiatry, Venray, Netherlands.
authors.forename: W M
authors.initials: WM
authors.lastname: Verhoeven
authors.affiliation: Vincent van Gogh Institut for Psychiatry, Centre of Excellence for Neuropsychiatry, Venray, Netherlands.
authors.forename: J I M
authors.initials: JI
authors.lastname: Egger
mesh_terms: D058165:22q11 Deletion Syndrome / Q000150:complications*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D014150:Antipsychotic Agents